SCNI vs VXRT

For growth investors, Vaxart, Inc.

(VXRT) is the stronger pick with 726. 7% revenue growth year-over-year, versus 99. 2% for Scinai Immunotherapeutics Ltd. (SCNI). Vaxart, Inc. (VXRT) offers the better valuation at 10. 6x trailing P/E, making it the more compelling value choice. Analysts rate Vaxart, Inc. (VXRT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Vaxart, Inc.

(VXRT) delivered a total return of -89. 7%, compared to -99. 8% for Scinai Immunotherapeutics Ltd. (SCNI). Over 10 years, the gap is even starker: VXRT returned -95. 8% versus SCNI's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Vaxart, Inc.

(VXRT) is the lower-risk stock at 0. 77β versus Scinai Immunotherapeutics Ltd. 's 1. 67β — meaning SCNI is approximately 118% more volatile than VXRT relative to the S&P 500. On balance sheet safety, Vaxart, Inc. (VXRT) carries a lower debt/equity ratio of 10% versus 28% for Scinai Immunotherapeutics Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Vaxart, Inc.

(VXRT) is pulling ahead at 726. 7% versus 99. 2% for Scinai Immunotherapeutics Ltd. (SCNI). On earnings-per-share growth, the picture is similar: Vaxart, Inc. grew EPS 150. 0% year-over-year, compared to -160. 0% for Scinai Immunotherapeutics Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vaxart, Inc.

(VXRT) is the more profitable company, earning 6. 9% net margin versus -633. 6% for Scinai Immunotherapeutics Ltd. — meaning it keeps 6. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VXRT leads at 7. 6% versus -575. 3% for SCNI. At the gross margin level — before operating expenses — VXRT leads at 90. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Vaxart, Inc.

(VXRT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 77)). Scinai Immunotherapeutics Ltd. (SCNI) carries a higher beta of 1. 67 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VXRT: -95. 8%, SCNI: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.